Corbus Pharmaceuticals Holdings
Open
$8.18
Prev. Close
$8.15
High
$8.20
Low
$8.16
Market Snapshot
$145.26M
-1.7
-3.64
36
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. The company is headquartered in Norwood, Massachusetts and currently employs 36 full-time employees. The company went IPO on 2014-10-24. The firm has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. The company is headquartered in Norwood, Massachusetts and currently employs 36 full-time employees. The company went IPO on 2014-10-24. The firm has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
Recently from Cashu
Corbus Pharmaceuticals Advances Oncology and Obesity Therapies with Promising Clinical Pipeline
Corbus Pharmaceuticals Holdings (Ticker: CRBP) focuses on novel therapeutic options and has made significant strides with its clinical pipeline. During a recent presentation, CEO Yuval Cohen emphasize…
Corbus Pharmaceuticals Advances Cancer and Obesity Treatments with Promising Drug Candidates
Corbus Pharmaceuticals Holdings (Ticker: CRBP) is advancing its key drug candidates, potentially paving the way for significant changes in treatment options for cancer and obesity. During a recent Jef…
Corbus Pharmaceuticals Advances CRB-701 Program for HPV-Related Head and Neck Cancer Treatment.
Corbus Pharmaceuticals Holdings (Ticker: CRBP) is making strides in the battle against recurrent or metastatic oropharyngeal head and neck cancer, a particularly aggressive form of the disease often a…
Corbus Pharmaceuticals Advances CRB-701 for HPV-Related Cancers Amid Mixed Market Reaction
Corbus Pharmaceuticals Holdings (Ticker: CRBP) demonstrates significant progress in its clinical development of CRB-701, a specialized antibody-drug conjugate targeting HPV-related oropharyngeal and c…